COUR Pharmaceuticals Secures $105M in Series A Financing

Chicago, IL, January 30, 2024 (Globe Newswire) -- COUR Pharmaceuticals has secured approximately $105 million in financing, marking a significant milestone in its pursuit of innovative therapeutic solutions. A clinical-stage biotechnology company dedicated to advancing first-in-class, disease-modifying therapies aimed at inducing antigen-specific tolerance for immune-mediated diseases, Cour has successfully concluded its Series A investment round.

Read full article here.